New Report: Drug companies in £1bn NHS rip-off

Treatments for cancer, arthritis and multiple sclerosis (MS) are among drugs costing the cash-strapped NHS over a billion pounds a year – despite public funding playing a substantial role in the medicines’ development. The new report, Pills and Profits: How drug...

Gilead admit that high prices aren’t to cover R&D

ACCESS DENIED: Report of the Inquiry of the All Party Parliamentary Group on HIV and AIDS into access to medicines in the developing world December 2014 http://impactaids.co.uk/wp-content/uploads/ACCESS-DENIED-APPG-Report-1.12.14.pdf...

The CEWG report

Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (2012) “Research and Development to meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination”...